Macromolecule-containing sustained release intraocular implants and related methods

• US 20050281861A1
• Filed: 04/27/2005
• Published: 12/22/2005
• Est. Priority Date: 04/30/2004
• Status: Abandoned Application

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Allergan Incorporated (Abbvie Incorporated)
• Inventors: Malone, Tom, Whitcup, Scott M., Hughes, Patrick M., Spada, Lon T., Devries, Gerald W., Blanda, Wendy M., Baciu, Peter, Edelman, Jeffrey
• Application Number:
  US11/116,698
• Publication Number:
  US 20050281861A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61F 9/0008 Introducing ophthalmic products into the ocular cavity or retaining products therein putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 31/724 Cyclodextrins
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/40 Cyclodextrins; Derivatives thereof
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 27/10 for accommodation disorders, e.g. myopia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Biocompatible intraocular drug delivery systems include a non-neurotoxic macromolecule therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The macromolecule therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent may be selected from the group consisting of anti-angiogenesis agents, ocular hemorrhage treatment agents, non-steroidal anti-inflammatory agents, growth factor inhibitors (such as VEGF inhibitors), growth factors, cytokines, antibodies, oligonucleotide aptamers, siRNA molecules and antibiotics. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

Claims

1. A sustained-release intraocular drug delivery system comprising:

a therapeutic component comprising a non-neurotoxic macromolecule therapeutic agent; and

a polymeric component associated with the therapeutic component to permit the therapeutic component to be released into the interior of an eye of an individual for at least about one week after the drug delivery system is placed in the eye.

2. The system of claim 1, wherein the polymeric component comprises a biodegradable polymer or biodegradable copolymer, the therapeutic component being associated with the polymeric component as a plurality of biodegradable particles.

3. The system of claim 1, wherein the polymeric component comprises a biodegradable polymer or biodegradable copolymer, the therapeutic component being associated with the polymeric component as a biodegradable implant.

4. The system of claim 1, wherein the therapeutic component comprises a macromolecule therapeutic agent selected from the group consisting of anti-bacterial agents, anti-angiogenic agents, anti-inflammatory agents, neuroprotectant agents, growth factor inhibitors, growth factors, cytokines, intraocular pressure reducing agents, ocular hemorrhage therapeutic agents, and combinations thereof.

5. The system of claim 1, wherein the therapeutic component comprises a macromolecule therapeutic agent selected from the group consisting of peptides, proteins, antibodies, antibody fragments, and nucleic acids.

6. The system of claim 1, wherein the therapeutic component comprises a short interfering ribonucleic acid or an oligonucleotide aptamer.

7. The system of claim 6, wherein the short interfering ribonucleic acid is effective in inhibiting cellular production of vascular endothelial growth factor or vascular endothelial growth factor receptors.

8. The system of claim 1, wherein the therapeutic component comprises an anti-angiogenic protein selected from the group consisting of endostatin, angiostatin, tumstatin, pigment epithelium derived factor, and a fusion protein comprising extracellular domains of a VEGF receptor coupled together by an Fc portion of an antibody.

9. The system of claim 1, wherein the therapeutic component comprises an antibody selected from the group consisting of anti-vascular endothelial growth factor antibodies, anti-vascular endothelial growth factor receptor antibodies, anti-integrin antibodies, fragments thereof, and combinations thereof.

10. The system of claim 1, wherein the therapeutic component comprises an oligonucleotide aptamer that binds vascular endothelial growth factor 165.

11. The system of claim 1, wherein the therapeutic component comprises a peptide that inhibits a urokinase.

12. The system of claim 1, wherein the therapeutic component comprises a therapeutic agent selected from the group consisting of non-steroidal anti-inflammatory agents, vascular endothelial growth factor inhibitors, antibiotics

13. The system of claim 1, wherein the therapeutic component comprises an agent selected from the group consisting of anecortave, hyaluronic acid, a hyaluronidase, ranibizumab, pegaptanib, and combinations thereof.

14. The system of claim 1, wherein the therapeutic component comprises an antibiotic selected from the group consisting of cyclosporine, gatifloxaxin, ofloxacin, rapamycin, epinastine, and combinations thereof.

15. The system of claim 1, wherein the therapeutic component comprises a macromolecule therapeutic agent selected from the group consisting of peptides, proteins, short interfering ribonucleic acids, antibodies, antibody fragments that are effective in treating intraocular conditions.

16. The system of claim 1, wherein the therapeutic component comprises a monoclonal antibody that binds vascular endothelial growth factor or a fragment thereof.

17. The system of claim 1, wherein the polymeric component comprises a polymer selected from the group consisting of biodegradable polymers, non-biodegradable polymers, biodegradable copolymers, non-biodegradable copolymers, and combinations thereof.

18. The system of claim 1, wherein the polymeric component comprises a polymer selected from the group consisting of poly-lactic acid (PLA), poly-glycolic acid (PGA), poly-lactide-co-glycolide (PLGA), polyesters, poly (ortho ester), poly(phosphazine), poly (phosphate ester), polycaprolactones, gelatin, collagen, derivatives thereof, and combinations thereof.

19. The system of claim 1, wherein the therapeutic component and the polymeric component are associated in the form of an implant selected from the group consisting of solid implants, semisolid implants, and viscoelastic implants.

20. The system of claim 1, wherein the therapeutic component and the polymeric component are associated with each other so that the release of the therapeutic component into the eye is by a method selected from the group consisting of diffusion, erosion, dissolution, osmosis, and combinations thereof.

21. The system of claim 1, wherein the therapeutic component and the polymeric component are associated with each other so that the therapeutic component is released into the eye for a time period from about ninety days to about one year after the system is placed in the interior of the eye.

22. The system of claim 1, wherein the therapeutic component and the polymeric component are associated with each other so that the therapeutic component is released into the eye for a time period greater than one year after the system is placed in the interior of the eye.

23. The system of claim 1, wherein the therapeutic component comprises at least one additional therapeutic agent other than the non-neurotoxic macromolecule therapeutic agent.

24. The system of claim 1, further comprising an excipient component.

25. The system of claim 1, wherein the drug delivery system is in the form of an extruded composition, and the non-neurotoxic macromolecule therapeutic agent is biologically active.

26. The system of claim 1 being structured to be placed in the vitreous of the eye.

27. The system of claim 1 which is formed as at least one of a rod, a wafer, and a particle.

28. A composition comprising the system of claim 1 and a ophthalmically acceptable carrier component.

29. The system of claim 1, wherein the therapeutic component and the polymeric component are associated to release an amount of the macromolecule therapeutic agent effective in providing a concentration of the macromolecule therapeutic agent in the vitreous of the eye from about 0.2 nM to about 5 μ

M.

30. The system of claim 1, wherein the therapeutic component and the polymeric component are associated to release a therapeutically effective amount of the macromolecule at a rate from about 0.003 μ

g/day to about 5000 μ

g/day.

38. A method of improving or maintaining vision of an eye of a patient, comprising the step of placing the drug delivery system of claim 1 into the interior of an eye of an individual.

39. The method of claim 38, wherein the therapeutic component comprises a therapeutic agent selected from the group consisting of an anti-angiogenesis agent, an ocular hemorrhage treatment agent, an non-steroidal anti-inflammatory agent, a growth factor inhibitor, a growth factor, a cytokine, an antibody, an oligonucleotide aptamer, an siRNA molecule and an antibiotic.

40. The method of claim 38, wherein the method is effective to treat a retinal ocular condition.

41. The method of claim 40, wherein the ocular condition includes retinal damage.

42. The method of claim 40, wherein the ocular condition is glaucoma or proliferative vitreoretinopathy

43. The method of claim 38, wherein the system is placed in the posterior segment of the eye.

44. The method of claim 38, wherein the system is placed in the eye using a trocar or a syringe.

45. The method of claim 38, wherein the drug delivery system comprises a biodegradable implant containing rapamycin, and placing the implant into the interior of the eye provides treatment of an ocular condition selected from the group consisting of uveitis and macular degeneration.

46. The method of claim 45, wherein the implant is placed into the eye to treat age related macular degeneration.

47. The method of claim 38, wherein the drug delivery system comprises a biodegradable implant containing an inhibitor of a vascular endothelial growth factor interaction with a vascular endothelial growth factor receptor, and placing the implant into the interior of the eye is effective to treat neovascularization of the eye.

31. A method of producing a sustained-release intraocular drug delivery system, comprising:

combining a non-neurotoxic macromolecule therapeutic agent and a polymeric material to form a drug delivery system suitable for placement in the interior of an eye of an individual and effective in releasing the macromolecule therapeutic agent into the eye for at least about one week after the drug delivery system is placed in the eye.

32. The method of claim 31, wherein the combined macromolecule therapeutic agent and the polymeric material are in the form of a particulate mixture, and the method further comprises extruding the mixture to form an extruded composition.

33. The method of claim 32, wherein the macromolecule therapeutic agent retains its biological activity when released into the eye.

34. The method of claim 32, further comprising forming the extruded composition into a population of polymeric particles or a population of implants structured for placement in the vitreous of the eye.

35. The method of claim 31, wherein the polymeric material comprises a biodegradable polymer, a non-biodegradable polymer, or a combination thereof.

36. The method of claim 31, wherein the macromolecule therapeutic agent is selected from the group consisting of peptides, proteins, short interfering ribonucleic acids, antibodies, antibody fragments, and combinations thereof, and the polymeric material comprises a biodegradable polymer selected from the group consisting of polylactides, poly-lactide-co-glycolides, polyesters, poly (ortho ester), poly (phosphazine), poly (phosphate ester), polycaprolactones, gelatin, collagen, and combinations thereof, and the method further comprises extruding the combination of the macromolecule therapeutic agent and polymeric material to form an intraocular implant.

37. The method of claim 31, wherein the combining is performed to form a drug delivery system that releases the macromolecule therapeutic agent into the eye at a rate from about 0.003 μ

g/day to about 5000 μ

g/day.